DSP cardiomyopathy is a distinct clinical entity characterized by left ventricular fibrosis and ventricular arrhythmias, necessitating a genotype-specific approach to diagnosis and risk stratification.
Supports DSP-specific evaluation in cardiomyopathy; leaves open prospective validation of risk stratification.
DSP cardiomyopathy is a distinct form of arrhythmogenic cardiomyopathy characterized by episodic myocardial injury, left ventricular fibrosis that precedes systolic dysfunction, and a high incidence of ventricular arrhythmias. A genotype-specific approach for diagnosis and risk stratification should be used.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: